Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Hepadnaviridae
gptkb:Hepatitis_B |
| gptkbp:associated_with |
chronic liver disease
extrahepatic manifestations increased liver cancer risk |
| gptkbp:caused_by |
Hepatitis B infection
|
| gptkbp:current_use |
gptkb:hepatocellular_carcinoma
liver failure hepatitis D virus co-infection |
| gptkbp:data_usage |
higher in healthcare settings
|
| gptkbp:discovered_by |
gptkb:1967
|
| gptkbp:duration |
may last for years
|
| gptkbp:family |
gptkb:Hepadnaviridae
|
| gptkbp:healthcare |
in many countries
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hepatitis B virus
|
| gptkbp:incubation_period |
30 to 180 days
|
| gptkbp:is_adopted_by |
may be necessary in severe cases
|
| gptkbp:is_popular_in |
approximately 257 million people infected
|
| gptkbp:is_protected_by |
vaccination
safe sex practices avoid sharing needles |
| gptkbp:is_vulnerable_to |
gptkb:HBV_vaccine
|
| gptkbp:metabolism |
used for assessing liver damage
|
| gptkbp:recommendation |
universal vaccination of infants
|
| gptkbp:research_focus |
immune response
vaccine development pathogenesis antiviral resistance |
| gptkbp:risk_factor |
travel to endemic areas
multiple sexual partners unprotected sex healthcare exposure injection drug use |
| gptkbp:seed_dispersal |
partially double-stranded DNA
|
| gptkbp:social_responsibility |
blood test
can lead to liver cancer can lead to liver cirrhosis may be asymptomatic can resolve spontaneously endemic in Asia and Africa |
| gptkbp:symptoms |
fatigue
nausea abdominal pain jaundice loss of appetite |
| gptkbp:transmission |
gptkb:healthcare_organization
sexual contact mother to child higher in chronic carriers |
| gptkbp:treatment |
antiviral medications
interferon therapy suppress viral replication prevent liver damage nucleos(t)ide analogs reduce risk of liver cancer |
| gptkbp:type_of |
adr
adw ayw |
| gptkbp:was_marked_by |
H Bs Ag
anti-H Bc anti-H Bs |